The new guidance on vaccines, such as those that protect against COVID-19, influenza, and RSV, will be released by the end of the summer, ahead of respiratory season.

A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal ...

Background Respiratory syncytial virus (RSV) remains the leading cause of serious viral bronchiolitis and pneumonia in infants and young children throughout the world. The burden of disease is ...

Background: Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory infections in children, yet biomarkers for assessing disease severity remain limited. Herein, we ...

About RSV Respiratory syncytial virus (RSV) is a contagious virus that causes widespread seasonal infections and can lead to serious respiratory conditions such as bronchiolitis and pneumonia.